Related references
Note: Only part of the references are listed.Burkitt Lymphoma: Pathogenesis and Immune Evasion
Jason M. God et al.
JOURNAL OF ONCOLOGY (2010)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Tenacigenin B derivatives reverse P-glycoprotein-mediated multidrug resistance in HepG2/Dox cells
Ying-Jie Hu et al.
JOURNAL OF NATURAL PRODUCTS (2008)
Biology and treatment of Burkitt's lymphoma
Jason T. Yustein et al.
CURRENT OPINION IN HEMATOLOGY (2007)
t(8;14;18): A 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia
Delong Liu et al.
MOLECULAR CANCER (2007)
Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells
B. M. Pickering et al.
ONCOGENE (2007)
Burkitt's lymphoma: Clinicopathologic features and differential diagnosis
Judith A. Ferry
ONCOLOGIST (2006)
Marsdenosides A-H, polyoxypregnane glycosides from Marsdenia tenacissima
J Deng et al.
PHYTOCHEMISTRY (2005)
Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter?
CA van den Bosch
LANCET ONCOLOGY (2004)
Burkitt's lymphoma: new insights into molecular pathogenesis
C Bellan et al.
JOURNAL OF CLINICAL PATHOLOGY (2003)
The BCL2 family: Regulators of the cellular life-or-death switch
S Cory et al.
NATURE REVIEWS CANCER (2002)